Alopecia Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Alopecia Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global alopecia market. The report identifies the key trends shaping and driving the global alopecia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global alopecia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData has estimated the global alopecia therapeutics market to be valued at $2,014.9m in 2010. It is forecast to grow at a CAGR (Compound Annual Growth Rate) of 4.8% for the next seven years to reach $2,804.4m by 2017. The market grew at a CAGR of 8.4% during the historic period (2005-2010). Propecia (finasteride) and Rogaine (minoxidil) are the only prescribed drugs for the treatment of alopecia. The patent expiry of Propecia in 2013 will impact the alopecia therapeutic market in the forecast period. However, Avodart (5α-reductase inhibitor) from GlaxoSmithKline which is an analogue to Propecia is in Phase III trials, and the drug is expected to launch by 2016. The major breakthrough in the Japan alopecia therapeutics market in the historical period was the approval of Propecia in 2006. The increasing patient population and expected launch of new drugs during the forecast period will drive the market growth.

Scope

The report provides information on the key drivers and challenges of the alopecia market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) alopecia market revenues data from 2005 to 2010, forecast for seven years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as androgen receptor antagonist, 5-alphareductase inhibitor, fatty acid derivative, immunosuppressant, potassium channel opener and prostaglandin agonist.
• Analysis of the current and future competition in the seven key countries alopecia market. Key market players covered are GlaxoSmithKline, Johnson & Johnson, Allergan, Cosmo Pharmaceuticals and R-Tech Ueno.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the alopecia market.
• Analysis of key recent licensing and partnership agreements in alopecia market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global alopecia market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global alopecia market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global alopecia market landscape? – Identify, understand and capitalize.

Table of contents

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Alopecia Therapeutics Market - Introduction 7
2.1 Overview 7
2.1.1 Types of Alopecia 7
2.2 Epidemiology 8
2.3 Etiology 8
2.4 Clinical Presentation/Symptoms 9
2.5 Prognosis 9
2.6 Diagnosis 9
2.6.1 Clinical Examination 9
2.6.2 Pathological test 11
2.7 Pathophysiology 11
2.8 Treatment 12
2.8.1 Androgenetic alopecia 12
2.8.2 Alopecia areata 14
2.9 GlobalData Pipeline Report Guidance 15

3 AlopeciaTherapeutics - Market Characterization 16
3.1 Alopecia Therapeutics Market Size (2005-2010) – Global 16
3.2 Alopecia Therapeutics Market Forecast (2010-2017) – Global 17
3.3 Alopecia Therapeutics Market Size (2005-2010) – The US 18
3.4 Alopecia Therapeutics Market Forecast (2010-2017) – The US 19
3.5 Alopecia Therapeutics Market Size (2005-2010) – France 20
3.6 Alopecia Therapeutics Market Forecast (2010-2017) – France 21
3.7 Alopecia Therapeutics Market Size (2005-2010) – Germany 22
3.8 Alopecia Therapeutics Market Forecast (2010-2017) – Germany 23
3.9 Alopecia Therapeutics Market Size (2005-2010) – Italy 24
3.10 Alopecia Therapeutics Market Forecast (2010-2017) – Italy 25
3.11 Alopecia Therapeutics Market Size (2005-2010) – Spain 26
3.12 Alopecia Therapeutics Market Forecast (2010-2017) – Spain 27
3.13 Alopecia Therapeutics Market Size (2005-2010) – The UK 28
3.14 Alopecia Therapeutics Market Forecast (2010-2017) – The UK 29
3.15 Alopecia Therapeutics Market Size (2005-2010) – Japan 30
3.16 Alopecia Therapeutics Market Forecast (2010-2017) – Japan 31
3.17 Drivers and Barriers for the Alopecia Therapeutics Market 32
3.17.1 Drivers for the Alopecia Market 32
3.18 Opportunity and Unmet Need 33
3.19 Key Takeaway 34

4 Alopecia Therapeutics Market - Competitive Assessment 35
4.1 Overview 35
4.2 Strategic Competitor Assessment 35
4.3 Product Profile for the Major Marketed Product in the Alopecia Therapeutics Market 36
4.3.1 Propecia (finasteride) 36
4.3.2 Rogaine (minoxidil) 37
4.3.3 Kenalog-10 (Triamcinolone acetonide) 38
4.4 Key Takeaway 39

5 Alopecia Therapeutics - Pipeline Assessment 40
5.1 Overview 40
5.2 Strategic Pipeline Assessment 40
5.3 Alopecia Therapeutics – Pipeline Analysis by Phase of Development 40
5.3.1 Alopecia Therapeutics – Phase III Clinical Pipeline 40
5.3.2 Alopecia Therapeutics – Phase II Clinical Pipeline 41
5.3.3 Alopecia Therapeutics – Phase I Pipeline 41
5.3.4 Alopecia Therapeutics – Discovery and Preclinical Pipeline 41
5.4 Alopecia Therapeutics – Pipeline by Mechanism of Action 42
5.5 Technology Trends Analytical Framework 43
5.6 Alopecia Therapeutics – Most Promising Drugs under Clinical Development 44
5.7 Most Promising Drug Profiles 45
5.7.1 Avodart (dutasteride) 45
5.8 Key Takeaway 45

6 Alopecia Therapeutics - Clinical Trials Mapping 46
6.1 Clinical Trials by Region/Country (US, EU5 & Japan) 46
6.2 Clinical Trials by Phase of Clinical Development 47
6.3 Clinical Trials by Trial Status 48
6.4 Clinical Trials by Sponsors 49
6.5 Brief Profiles of Top 10 Companies Participating in Clinical Trials 50

7 Alopecia Therapeutics Market - Strategic Assessment 51
7.1 Key Events Impacting the Future Market 51
7.2 Future Market Competition Scenario 52

8 Alopecia Market - Future Players 53
8.1 Introduction 53
8.2 Company Profiles 53
8.2.1 Johnson & Johnson 53
8.2.2 GlaxoSmithKline 55
8.2.3 Merck & Co. 56
8.2.4 Allergan Inc. 58
8.2.5 Cosmo Pharmaceuticals 59
8.2.6 R-Tech Ueno 59
8.3 Key Takeaway 60

9 Alopecia Therapeutics - Licensing and Partnership Deals 61

10 Alopecia Market Therapeutics - Appendix 62
10.1 Market Definitions 62
10.2 Acronyms 62
10.3 Research Methodology 63
10.3.1 Coverage 63
10.3.2 Secondary Research 63
10.3.3 Forecasting 64
10.3.4 Primary Research 66
10.3.5 Expert Panel Validation 67
10.4 Contact Us 67
10.5 Bibliography 67

List of Tables

Table 1: Alopecia Therapeutics Market, Global, Revenue ($m), 2005–2010 16
Table 2: Alopecia Therapeutics Market, Global, Forecast ($m), 2010–2017 17
Table 3: Alopecia Therapeutics Market, The US, Revenue ($m), 2005–2010 18
Table 4: Alopecia Therapeutics Market, The US, Forecasts ($m), 2010–2017 19
Table 5: Alopecia Therapeutics Market, France, Revenue ($m), 2005–2010 20
Table 6: Alopecia Therapeutics Market, France, Forecasts ($m), 2010–2017 21
Table 7: Alopecia Therapeutics Market, Germany, Revenue ($m), 2005–2010 22
Table 8: Alopecia Therapeutics Market, Germany , Forecasts ($m), 2010–2017 23
Table 9: Alopecia Therapeutics Market, Italy, Revenue ($m), 2005–2010 24
Table 10: Alopecia Therapeutics Market, Italy, Forecasts ($m), 2010–2017 25
Table 11: Alopecia Therapeutics, Spain, Revenue ($m), 2005–2010 26
Table 12: Alopecia Therapeutics Market, Spain, Forecast ($m), 2010–2017 27
Table 13: Alopecia Therapeutics, The UK, Revenue ($m), 2005–2010 28
Table 14: Alopecia Therapeutics Market, The UK, Forecasts ($m), 2010–2017 29
Table 15: Alopecia Therapeutics, Japan, Revenue ($m), 2005–2010 30
Table 16: Alopecia Therapeutics Market, Japan, Forecast ($m), 2010–2017 31
Table 17: Alopecia Therapeutics Market, Phase III Pipeline, 2011 40
Table 18: Alopecia Therapeutics Market, Phase II Pipeline, 2011 41
Table 19: Alopecia Therapeutics Market, Phase I Pipeline, 2011 41
Table 20: Alopecia Therapeutics Market, Discovery and Preclinical Pipeline, 2011 41
Table 21: Alopecia Therapeutics Market, Global, Most Promising Drugs Under Clinical Development, 2011 44
Table 22: Alopecia Therapeutics, Global, Clinical Trials, 2011 46
Table 23: Alopecia Therapeutics, Global, Clinical Trials by Phase, 2011 47
Table 24: Alopecia Therapeutics, Global, Clinical Trials by Status of Development, 2011 48
Table 25: Alopecia Therapeutics, Global, Prominent Sponsors, 2011 50
Table 26: Alopecia Therapeutics, Global, Top Ten Companies by Phase, 2011 50
Table 27: Johnson and Johnson, Alopecia Marketed Products, 2011 54
Table 28: GlaxoSmithKline, Alopecia Pipeline Products, 2011 56
Table 29: Novartis AG, Alopecia Marketed Products, 2011 58
Table 30: Alopecia Therapeutics, Global, Deals, 2010 61

List of Figures

Figure 1: Norwood-Hamilton Scale of Male Pattern Baldness 10
Figure 2: Ludwig Scale of Female Pattern Baldness 11
Figure 3: Androgenetic alopecia (Males), Treatment Protocol 12
Figure 4: Androgenetic alopecia (Females), Treatment Protocol 13
Figure 5: Alopecia Areata, Treatment Protocol 14
Figure 6: Alopecia Therapeutics Market, Global, Revenue ($m), 2005–2010 16
Figure 7: Alopecia Therapeutics Market, Global, Forecast ($m), 2010–2017 17
Figure 8: Alopecia Therapeutics Market, The US, Revenue ($m), 2005–2010 18
Figure 9: Alopecia Therapeutics Market, The US, Forecasts ($m), 2010–2017 19
Figure 10: Alopecia Therapeutics Market, France, Revenue ($m), 2005–2010 20
Figure 11: Alopecia Therapeutics Market, France, Forecasts ($m), 2010–2017 21
Figure 12: Alopecia Therapeutics Market, Germany, Revenue ($m), 2005–2010 22
Figure 13: Alopecia Therapeutics Market, Germany , Forecasts ($m), 2010–2017 23
Figure 14: Alopecia Therapeutics Market, Italy, Revenue ($m), 2005–2010 24
Figure 15: Alopecia Therapeutics Market, Italy, Forecasts ($m), 2010–2017 25
Figure 16: Alopecia Therapeutics, Spain, Revenue ($m), 2005–2010 26
Figure 17: Alopecia Therapeutics Market, Spain, Forecast ($m), 2010–2017 27
Figure 18: Alopecia Therapeutics, The UK, Revenue ($m), 2005–2010 28
Figure 19: Alopecia Therapeutics Market, The UK, Forecasts ($m), 2010–2017 29
Figure 20: Alopecia Therapeutics, Japan, Revenue ($m), 2005–2010 30
Figure 21: Alopecia Therapeutics Market, Japan, Forecast ($m), 2010–2017 31
Figure 22: Opportunity and Unmet Need in the Alopecia Therapeutics Market 33
Figure 23: Strategic Competitor Assessment of the Marketed Products in Alopecia, 2011 36
Figure 24: Alopecia Therapeutics Market, Clinical Pipeline by Mechanism of Action (%), 2011 42
Figure 25: Alopecia Therapeutics Market – Clinical Pipeline by Phase of Development (%), 2011 43
Figure 26: Technology Trends Analytics Framework, 2011 43
Figure 27: Technology Trends Analytics Frame Work – Description, 2011 44
Figure 28: Alopecia Therapeutics, Global, Clinical Trials by Country, 2011 46
Figure 29: Alopecia Therapeutics, Global, Clinical Trials by Phase (%), 2011 47
Figure 30: Alopecia Therapeutics, Global, Clinical Trials by Status of Development (%), 2011 48
Figure 31: Alopecia Therapeutics, Global, Overall Sponsors (%), 2011 49
Figure 32: Alopecia Therapeutics, Global, Prominent Sponsors (%), 2011 49
Figure 33: Alopecia Therapeutics, Global, Top Ten Companies by Phase, 2011 50
Figure 34: Alopecia Therapeutics Market, Drivers and Restraints, 2011 51
Figure 35: Implications for Future Market Competition in the Alopecia Therapeutics Market, 2011 52
Figure 36: Alopecia Therapeutics Market, Clinical Pipeline by Company, 2011 53
Figure 37: GlobalData Market Forecasting Model 66